Acadian Asset Management
RAPP

Acadian Asset Management’s Rapport Therapeutics RAPP Stock Holding History

Acadian Asset Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39K Sell
957
-10,832
-92% -$398K ﹤0.01% 1876
2026
Q1 		$367K Sell
11,789
-32,502
-73% -$914K ﹤0.01% 1438
2025
Q4 		$1.34M Buy
44,291
+42,813
+2,897% +$1.18M ﹤0.01% 1028
2025
Q3 		$43K Buy
+1,478
New +$26.4K ﹤0.01% 1661

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Acadian Asset Management's RAPP Position: Q2 2026 in Review

Acadian Asset Management reduced its Rapport Therapeutics (RAPP) stake by 92% in Q2 2026, selling an estimated $398K and leaving 957 shares worth $39K. The position accounts for ﹤0.01% of the portfolio, ranked #1876.

Acadian Asset Management first reported a position in RAPP in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.34M in Q4 2025. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Acadian Asset Management held 957 shares of Rapport Therapeutics worth $39K as of Q2 2026.
  • Acadian Asset Management sold 10,832 Rapport Therapeutics shares in Q2 2026, an estimated $398K.
  • Rapport Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1876 holding.
  • Acadian Asset Management first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Acadian Asset Management's Rapport Therapeutics position peaked at $1.34M in Q4 2025.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.